SCHEMBL6433093

SCHEMBL6433093

O=C(O)c1ccc(C=NNc2nc3nonc3nc2NCc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.45
DDX3X O00571 1/20 0.44
MAPT P10636 8/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 2/20 0.42
HSP90AA1 P07900 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
BIRC5 O15392 1/20 0.42
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 2/20 0.41
AURKA O14965 1/20 0.41
MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416062 0.89 BIRC5 (0.46) GAADDX3XMAPTMEN1KMT2A
SCHEMBL6414142 0.88 MAPT (0.43) GAADDX3XMAPTMEN1KMT2A
SCHEMBL6419253 0.86 PHGDH (0.57) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6419258 0.86 PHGDH (0.57) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6413566 0.84 BIRC5 (0.48) GAADDX3XMAPTMEN1KMT2A
SCHEMBL6413667 0.83 DHODH (0.45) DDX3XMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6418379 0.81 MAPK1 (0.48) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6435175 0.80 BIRC5 (0.68) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6435171 0.80 BIRC5 (0.68) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6413294 0.80 GAA (0.46) GAAMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885DDX3X 2134/4885MAPT 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.